ArticleAsian Pacific journal of cancer prevention : APJCP2023
Dosimetric Comparison between Acuros XB (AXB) and Anisotropic Analytical Algorithm (AAA) in Volumetric Modulated Arc Therapy.
Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dosimetric impact of knowledge-based automated planning using HyperArc for angiosarcoma of the scalp.Physical and engineering sciences in medicine · 2026Article
- Dosimetric assessment of conventional and advanced algorithms in clinical stereotactic radiotherapy.Precision radiation oncology · 2025Article
- Dosimetric Validation of Treatment Planning System for Volumetric Modulated Arc Therapy Using AAPM Medical Physics Practice Guideline 5.b.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Dosimetric Impact of AAA and AXB Dose Calculation Algorithm in VMAT Treatment Planning for Rectal Tumors.Journal of medical physicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDose calculation accuracy between Anisotropic Analytical Algorithm (AAA) and Acuros XB (AXB) for various megavoltage (MV) photon beams for both flattening filter (FF) and flattening filter free (FFF) beams and to validate the accuracy of these dose calculations using inhomogeneous phantom in volumetric modulated arc therapy (VMAT). MATERIAL AND
methodsA Cheese Phantom having 20 holes that can be filled with all virtual water plugs or set of density calibration plugs was used for VMAT planning using two different algorithms using either single or double arc. Further phantom was used irradiate plan in linear accelerator and the point doses measured using a 0.053 cc A1SL ionization chamber along electrometer . Different plans, cylindrical shape, C-shaped and donut targets were planned 6MV, 10MV, 6FFF MV and 10FFF MV beam energy.
resultThe minimum average mean dose difference was 1.2% for PTV structures between AAA and AXB (p=0.02). Apart from these structures, the following density plugs have a more than 2% difference in maximum dose with statistical significance. (i) Solid water (MD=6.1%, p=0.016), (ii) Bone 200 (2.3%, p=0.029), (iii) CB_30% (MD=2.4%, p=0.050) and (iv) Cortical bone (MD=4.3%, p=0.018). In 6MV FFF and 10 MV FFF plans, the difference between AAA and AXB was not statistically significant (Fig 3). The Conformity index for the AAA less than that of AXB, in all energies and for all the PTVs. The CI was better in AXB than AAA, but the CI was not having much variation due to changes in beam energies, particularly for Cylinder shaped PTV.
conclusionAll combinations of beam energy AAA showed higher values in the maximum dose than the Acuros XB, except for the lung insert. Nonetheless, AAA showed a higher mean dose than the Acuros XB. Differences between these two algorithms for most of the beam energies are minimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.